The immunobiological effects of interleukin-2 in vivo.
作者信息
Janssen R A, Mulder N H, The T H, de Leij L
机构信息
Department of Clinical Immunology, University Hospital Groningen, The Netherlands.
出版信息
Cancer Immunol Immunother. 1994 Oct;39(4):207-16. doi: 10.1007/BF01525983.
Abstract
摘要
相似文献
1
The immunobiological effects of interleukin-2 in vivo.白细胞介素-2在体内的免疫生物学效应。
Cancer Immunol Immunother. 1994 Oct;39(4):207-16. doi: 10.1007/BF01525983.
2
[Prospects for cancer immunotherapy using interleukin-1(IL-1) and interleukin-2(IL-2)].使用白细胞介素-1（IL-1）和白细胞介素-2（IL-2）进行癌症免疫治疗的前景
Nihon Rinsho. 1983;41(4):868-74.
3
Immunotherapy of cancer with interleukin-2 and lymphocytes (LAK or TIL).
Pharmacol Res. 1992 Sep;26 Suppl 2:104-5. doi: 10.1016/1043-6618(92)90619-m.
4
Local and regional immunotherapy of cancer with interleukin 2.白细胞介素2对癌症的局部和区域免疫治疗
J Cancer Res Clin Oncol. 1990;116(1):1-7. doi: 10.1007/BF01612631.
5
Immunotherapy of human cancers with tumor-infiltrating lymphocytes and systemic infusions of interleukin-2.
Cancer Invest. 1990;8(2):317-8. doi: 10.3109/07357909009017604.
6
Immunotherapy of cancer using interleukin 2: current status and future prospects.使用白细胞介素-2进行癌症免疫治疗：现状与未来前景
Immunol Today. 1988 Feb;9(2):58-62. doi: 10.1016/0167-5699(88)91261-3.
7
Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
Cancer J Sci Am. 2000 Feb;6 Suppl 1:S2-7.
8
Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?监测白细胞介素-2癌症免疫疗法时，哪些免疫学参数在临床上至关重要？
J Biol Regul Homeost Agents. 1999 Apr-Jun;13(2):110-4.
9
[Interleukin-2 and cancer immunotherapy].[白细胞介素-2与癌症免疫疗法]
Vopr Onkol. 1989;35(2):141-50.
10
[Alloimmunization in the treatment of malignant diseases].
Cesk Gynekol. 1985 Nov;50(9):675-6.
引用本文的文献
1
Interleukin-2 affects steroidogenesis and numbers of bovine ovarian granulosa cells but not thecal cellsin vitro.白细胞介素-2在体外影响牛卵巢颗粒细胞的类固醇生成和数量，但不影响卵泡膜细胞。
Endocrine. 1995 Dec;3(12):899-905. doi: 10.1007/BF02738895.
2
Local therapy of cancer with free IL-2.使用游离白细胞介素-2对癌症进行局部治疗。
Cancer Immunol Immunother. 2008 Jul;57(7):931-50. doi: 10.1007/s00262-008-0455-z.
3
Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients.低剂量白细胞介素-2可诱导黑色素瘤患者体内的细胞因子级联反应、嗜酸性粒细胞增多以及短暂的Th2偏移。
Cancer Immunol Immunother. 2005 Nov;54(11):1095-105. doi: 10.1007/s00262-005-0701-6. Epub 2005 May 12.
4
Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma.癌症局部白细胞介素-2治疗的进一步发展：对移植的小鼠结肠癌进行多次与单次白细胞介素-2治疗
Cancer Immunol Immunother. 2004 May;53(5):445-52. doi: 10.1007/s00262-003-0490-8. Epub 2004 Feb 10.
5
Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model.在小鼠结肠癌模型中，用氧氮磷啶药物和分泌白细胞介素-2的细胞进行化学免疫疗法的协同抗肿瘤作用。
Med Oncol. 1999 Dec;16(4):267-78. doi: 10.1007/BF02785873.
6
Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.皮下注射白细胞介素-2治疗转移性肾细胞癌：细胞因子非肾清除的证据。
Br J Cancer. 1997;75(12):1842-8. doi: 10.1038/bjc.1997.314.
7
Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells.白细胞介素-2转染的结肠癌细胞在体外诱导的免疫反应：主要诱导淋巴因子激活的杀伤细胞
J Mol Med (Berl). 1996 Jan;74(1):43-9. doi: 10.1007/BF00202071.
8
Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.静脉注射BIS-1 F(ab')2对肾细胞癌患者的免疫调节作用。
Br J Cancer. 1995 Sep;72(3):795-9. doi: 10.1038/bjc.1995.414.
本文引用的文献
1
Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.肾细胞癌患者皮下注射重组白细胞介素-2治疗期间早期可溶性CD8血浆水平与疗效相关。
Br J Cancer. 1993 May;67(5):1118-21. doi: 10.1038/bjc.1993.205.
2
Response of soluble IL-2 receptor levels to repeated cycles of IL-2 immunotherapy/chemotherapy.可溶性白细胞介素-2受体水平对白细胞介素-2免疫疗法/化学疗法重复周期的反应。
Eur J Cancer. 1993;29A(6):928. doi: 10.1016/s0959-8049(05)80445-9.
3
4
HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.在肾细胞癌患者接受皮下重组白细胞介素-2治疗期间，表达HLA-Dr的CD8bright细胞仅短暂存在于循环系统中。
Cancer Immunol Immunother. 1993;36(3):198-204. doi: 10.1007/BF01741092.
5
Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion.浸润结肠癌的淋巴细胞对自体肿瘤的特异性免疫识别：通过细胞因子分泌进行分析
Cancer Immunol Immunother. 1993;36(1):1-8. doi: 10.1007/BF01789124.
6
B7/BB-1 is a leucocyte differentiation antigen on human dendritic cells induced by activation.B7/BB-1是人类树突状细胞经激活后诱导产生的一种白细胞分化抗原。
Immunology. 1993 Aug;79(4):616-20.
7
Requirements for CD28-dependent T cell-mediated cytotoxicity.CD28 依赖性 T 细胞介导的细胞毒性的要求。
J Immunol. 1993 Mar 15;150(6):2091-101.
8
In vitro inhibition of interleukin-2-induced defective polymorphonuclear chemotaxis by TNF inhibitor.
Eur J Haematol. 1993 Jul;51(1):13-7. doi: 10.1111/j.1600-0609.1993.tb00598.x.
9
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.抗CD3抗体序贯大剂量推注白细胞介素-2用于转移性黑色素瘤和晚期肾细胞癌患者的I B期临床试验：临床和免疫效应
J Clin Oncol. 1993 Aug;11(8):1496-505. doi: 10.1200/JCO.1993.11.8.1496.
10
Transendothelial migration activity of lymphokine-activated killer (LAK) cells.淋巴因子激活的杀伤细胞（LAK细胞）的跨内皮迁移活性。
J Immunol. 1993 Aug 1;151(3):1663-72.
Zotero 插件